Pemigatinib and Immunotherapy for Advanced Cholangiocarcinoma
Author Information
Author(s): Guo Jiamin, Sun Lingqi, Chen Ye, Ma Ji
Primary Institution: West China Hospital, Sichuan University, Chengdu, Sichuan, China
Hypothesis
Can pemigatinib combined with immunotherapy and stereotactic body radiation therapy effectively treat FGFR2 fusion-positive advanced intrahepatic cholangiocarcinoma with brain metastasis?
Conclusion
The combination therapy of pemigatinib, immunotherapy, and stereotactic body radiation therapy was effective and well-tolerated in a patient with advanced cholangiocarcinoma and brain metastasis.
Supporting Evidence
- FGFR2 fusions occur in 13%–20% of patients with intrahepatic cholangiocarcinoma.
- Brain metastasis in advanced intrahepatic cholangiocarcinoma is extremely rare.
- The patient experienced significant tumor shrinkage after treatment with the combination therapy.
Takeaway
A patient with a rare type of liver cancer had their tumors shrink after receiving a special combination of treatments, including a targeted drug and radiation.
Methodology
The patient was treated with pemigatinib, immunotherapy (tislelizumab), and stereotactic body radiation therapy for brain metastasis.
Potential Biases
The inherent bias of a single-case study may affect the reliability of the results.
Limitations
The study lacks a control group and is based on a single case, limiting the generalizability of the findings.
Participant Demographics
The patient was a 58-year-old male from China.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website